Companies Owned by Pfizer (2026)

Is Pfizer a Delaware company, and why does that matter here?

Pfizer Inc. is incorporated in Delaware, even though its operational headquarters is in New York City. That split — a Delaware legal home with operations somewhere else — is the single most common pattern among large US public companies, and it is the reason a page about the companies Pfizer owns belongs on a Delaware site at all. The entity that legally holds every Pfizer subsidiary and brand is a Delaware corporation, and Delaware law governs how that parent is structured, how its board operates, and how disputes among its owners are resolved.

Understanding ownership through this lens is useful because Delaware incorporation is about the container, not the contents. Pfizer makes vaccines and oncology drugs in facilities around the world, yet the company you buy a share of on the New York Stock Exchange is a Delaware entity. The same separation applies to the smallest business: when you form a Delaware LLC, the state of incorporation is where the legal entity lives, while your actual work can happen anywhere on earth. Pfizer is simply this idea at enormous scale.

Throughout this page, "owned" means Pfizer holds a controlling or wholly owned interest in the business — the kind of ownership reflected in its consolidated financial statements and its subsidiary list. We deliberately separate that from collaborations, minority stakes, and former businesses, because brand association is not the same as ownership, and getting that distinction right is the entire point.

It is worth being precise about why Delaware, specifically, sits at the top of so many corporate trees. Delaware is not a tax haven in the way the phrase is often used; Pfizer pays federal corporate tax like any other US company and pays income tax in the many states and countries where it actually earns money. What Delaware offers instead is legal machinery: a corporation statute drafted to give boards and shareholders clear, well-tested rules, and a court system that has spent more than a century interpreting those rules consistently. For a company that constantly raises money, issues stock to pay for acquisitions, and is itself a potential acquisition target, that predictability is worth more than a few points of state tax. The same logic scales all the way down to a single-member LLC, which is why the Delaware choice is not just a big-company habit.

What companies does Pfizer actually own?

Pfizer has grown for more than a century by acquiring other companies and folding them into the parent. The clearest examples of businesses it genuinely owns are former public companies that Pfizer bought outright and now consolidates as subsidiaries. These are not licensing deals or partnerships — Pfizer acquired the whole company.

• Seagen — a Seattle-area cancer-drug specialist Pfizer acquired in a deal worth roughly $43 billion that closed in December 2023. It is now a wholly owned subsidiary.
• Hospira — an injectable-drugs and infusion-systems maker Pfizer acquired in 2015, which became the backbone of its sterile-injectables business.
• Array BioPharma — a Colorado oncology company Pfizer bought in 2019, bringing targeted cancer therapies into the fold.
• Arena Pharmaceuticals — an immuno-inflammation company Pfizer acquired in a deal that completed in 2022.
• Global Blood Therapeutics (GBT) — a sickle-cell disease company Pfizer acquired in 2022.
• Trillium Therapeutics — an immuno-oncology company Pfizer acquired in a deal completed in late 2021.

Each of these was an independent, often publicly traded company before Pfizer bought it. After the acquisition closed, it ceased to trade on its own and became part of the Pfizer group. Pfizer's annual report on Form 10-K includes an exhibit listing its subsidiaries across many countries, which is the authoritative place to confirm the full legal structure rather than guessing from brand names.

A pattern runs through that list: most of what Pfizer owns, it bought. Unlike a company that grows purely by inventing products in its own labs, Pfizer has long used acquisition as a growth engine, purchasing companies that already have approved medicines, late-stage candidates, or specialized technology platforms, and then operating them inside the group. Hospira gave it scale in sterile injectables. Array and Arena added pipelines in oncology and inflammation. Global Blood Therapeutics and Trillium added programs in sickle-cell disease and immuno-oncology. Seagen added an entire antibody-drug-conjugate platform. This is why an ownership list reads like an acquisition history — because for a company of Pfizer's size, the two are nearly the same thing.

One caution is built into a list like this: acquisition values and closing dates are concrete facts, but the day-to-day status of an acquired pipeline can change. A drug that came with an acquisition may later be discontinued, sold, or withdrawn, and that does not change who owns the company — only what that company is working on. Where this page names specific medicines, treat them as illustrations of what an acquisition brought in, not as a guarantee that every product remains on the market today. The ownership of the subsidiary is the durable fact; its product roster evolves.

What was the Seagen acquisition, and why was it so significant?

Seagen is the headline name in any honest list of companies Pfizer owns. Pfizer agreed to buy it for $229 per share in cash, valuing the deal at about $43 billion net of cash acquired, and the transaction closed in December 2023 after clearing regulatory review. It was among the largest biopharmaceutical acquisitions in years and reshaped Pfizer's cancer portfolio in a single move.

What Pfizer bought was not just a company but a platform: Seagen pioneered antibody-drug conjugates, a technology that links a targeting antibody to a cancer-killing payload. Medicines that came with the deal include Adcetris, Padcev, Tukysa, and Tivdak. To satisfy competition regulators, Pfizer agreed to give up the US royalty stream on one overlapping product, an example of how large acquisitions are reshaped by antitrust review before they close. Today Seagen operates inside Pfizer rather than as an independent company, which is exactly what "owned" means in this context.

The Seagen deal also illustrates how a clean entity structure makes a huge transaction possible. Seagen was a single company with a defined set of assets, shareholders, and contracts, which let Pfizer buy "the whole thing" in one cash transaction at a per-share price. Acquisitions work this way because the target is a discrete legal container: you can value it, negotiate over it, and transfer it without having to untangle it from a dozen other businesses. The same property that lets a giant buy another giant is what lets a founder sell a small company — and it is one reason holding your business in its own clean entity, rather than running it as a sole proprietor, matters long before any sale is on the table.

For most readers the relevant lesson is not the size of the check but the shape of the deal. Pfizer did not buy a list of patents scattered across the seller's personal accounts; it bought a company. When you form a Delaware LLC and keep your brand, contracts, and bank account inside it, you are building exactly the kind of clean container that makes a future transaction simple rather than painful. That is the through-line from a $43 billion deal to a $397 formation: the entity is what changes hands.

Which brands does Pfizer own versus merely sell?

This is where most ownership lists go wrong, because a famous product on a Pfizer label does not always mean Pfizer alone owns it. Some of Pfizer's biggest sellers are shared with partners under co-development or co-promotion agreements. Telling the two apart is the difference between an accurate ownership picture and a misleading one.

The table makes the point that owning the company that makes a drug is different from sharing a single product with another company. Pfizer fully owns the Prevnar vaccine franchise and oncology brands like Ibrance, and it owns the Seagen medicines because it owns Seagen. But Comirnaty and Eliquis — two of its largest revenue lines — are collaborations, which is why neither BioNTech nor Bristol Myers Squibb appears on any honest list of companies Pfizer owns.

The reason this matters for an ownership page is that revenue size tempts people to equate a big product with a wholly owned business. Eliquis is one of the highest-grossing medicines in the world and carries the Pfizer name in many markets, yet the economics are split with Bristol Myers Squibb under a long-standing alliance. Comirnaty generated enormous sales during the pandemic, but BioNTech holds the foundational technology and shares the profits. In both cases Pfizer's slice of the revenue is real, but the partner is a separate, independent public company. If you were drawing Pfizer's true ownership tree, you would draw a dotted line — a contract — to these partners, not a solid line of ownership, and the distinction is exactly the kind a careful founder learns to make about their own deals.

What companies are commonly mistaken as Pfizer-owned but are NOT?

Several well-known names get attached to Pfizer in casual lists, usually because of a past relationship, a shared product, or a spin-off. None of the following is currently owned or controlled by Pfizer, and including them would be a factual error.

• BioNTech — Pfizer's COVID-19 vaccine partner. It is an independent, publicly traded German company that co-developed Comirnaty. Pfizer collaborates with it; it does not own it.
• Haleon — the consumer-health business (Advil, Centrum, Sensodyne) that emerged from a Pfizer–GSK joint venture and listed separately in 2022. Pfizer has been selling down its stake, which fell into the mid-20-percent range during 2024. A shrinking minority holding is an investment, not ownership.
• Viatris — created in 2020 by combining Pfizer's off-patent Upjohn business with Mylan. It trades independently. Older Pfizer brands that moved into Upjohn, such as off-patent Lipitor and Viagra, went with it and are no longer Pfizer-owned.
• GSK and Bristol Myers Squibb — partners and competitors, not subsidiaries. Pfizer co-markets Eliquis with Bristol Myers Squibb, but the two companies are entirely separate.

The recurring theme is that history and partnership create the impression of ownership without the substance. When in doubt, the test is simple: does Pfizer consolidate the company in its financial statements and list it as a subsidiary? If not, Pfizer does not own it.

This distinction is not pedantic — it has real consequences for how you read any "companies owned by" list. A minority stake, like the one Pfizer has been winding down in Haleon, gives an investor economic exposure and perhaps a board seat, but not control; the company runs its own affairs and reports its own results. A collaboration, like Pfizer's work with BioNTech, splits the economics of a single product without merging the two companies. A spin-off, like Viatris, hands a business to a new set of shareholders and cuts the old parent loose. Only outright acquisition, where one company absorbs another into its consolidated group, is "ownership" in the strict sense this page uses. Keeping those four relationships straight is what separates an accurate map from a pile of loose brand associations.

What happened to Pfizer's consumer-health and off-patent businesses?

Pfizer was once a much broader company that sold everyday consumer products and a large catalog of off-patent medicines. Over several years it deliberately narrowed its focus to innovative, patent-protected drugs and vaccines, shedding the rest into separate companies. This is why brands people remember as "Pfizer" are now housed elsewhere.

The consumer-health portfolio went into a joint venture with GSK in 2019 and then became the standalone company Haleon in 2022, carrying household names like Advil and Centrum. The off-patent established- medicines business, Upjohn, merged with Mylan in 2020 to form Viatris. In both cases Pfizer's holders received the new shares, and Pfizer has since reduced or exited its positions. These moves are a useful reminder that corporate ownership is a moving picture: a brand under one company this decade can sit under a different parent the next, which is exactly why founders structure entities they can later sell or spin out.

There is a strategic reason a company deliberately gets smaller in scope even as it stays large in revenue. By concentrating on patented, higher-margin innovative medicines and offloading consumer products and off-patent drugs, Pfizer made each remaining business easier to value and each divested business easier to sell. Investors could then own the piece they actually wanted — the focused pharma company, the standalone consumer-health company, or the off-patent generics company — rather than one conglomerate blending all three. None of that is possible without clean entities. You cannot cleanly spin out a business that was never a separate legal container in the first place, which is the quiet argument for forming distinct entities even when a business is small.

Are Pfizer's subsidiaries incorporated in Delaware too?

Some are and some are not. A Delaware parent like Pfizer can own subsidiaries formed in Delaware, in other US states, or in foreign countries — and Pfizer's subsidiary list spans many jurisdictions because it operates globally. There is no requirement that a parent and its subsidiaries share a single state of incorporation. A US holding subsidiary might be a Delaware corporation while a manufacturing entity is organized where its plant sits and an international arm is formed under local law abroad.

For founders, the practical lesson is that the state of incorporation is a choice made entity by entity, for legal and tax reasons, independent of where the work happens. That is why a non-resident can own a Delaware LLC for non-residents while living anywhere, and why a Delaware parent can sit above a web of subsidiaries formed all over the map. The container and the contents are separate decisions — at Pfizer's scale and at yours.

Large groups also use multiple entities for reasons that have nothing to do with secrecy and everything to do with order. Separate subsidiaries can ring-fence the liabilities of one business from another, hold intellectual property in a dedicated entity, simplify local regulation in a given country, and make a future sale or carve-out of one unit clean. A single founder rarely needs that complexity on day one, but the principle is identical: an entity is a boundary, and boundaries are what let you separate risk, ownership, and accounting cleanly. Understanding that is more valuable than memorizing which subsidiary sits in which state, because it tells you why the structure exists at all.

What does Pfizer's structure teach a founder about Delaware?

The most useful insight from Pfizer is that one Delaware parent can hold many separable businesses cleanly. Each acquisition — Seagen, Hospira, Array — sits inside the group as a distinct legal entity, which keeps ownership, liability, and future transactions tidy. If Pfizer ever wants to sell or carve out a business, having it as a separate entity makes that far simpler, exactly as it did when it spun off Upjohn into Viatris.

A founder forming a single Delaware LLC formation is using the same building block at the opposite end of the scale. One recognized US legal home can hold your brand today and be sold, partnered, or expanded tomorrow. Delaware is the default for this because its corporate law is predictable and its Court of Chancery resolves business disputes with specialized judges and a deep case-law record. The same qualities that make Delaware the home of pharma giants make it a clean choice for a one-person company.

Consider what would change if Pfizer had grown by simply absorbing each acquisition into one undifferentiated mass instead of holding them as distinct entities. Untangling a single business to sell it would mean tracing which contracts, employees, patents, and liabilities belonged to which product line — a forensic exercise rather than a transfer. By keeping acquired companies as entities, the parent preserves the option to act on each one independently later. Optionality is the real benefit of clean structure: you do not have to know today whether you will sell, partner, raise money, or hold forever, because a well-formed entity keeps every one of those doors open. A founder who incorporates early buys the same optionality for almost nothing.

That is the bridge from this history to a real decision. You will not buy a $43 billion oncology company, but you can adopt the same structural logic — a Delaware entity as a durable, transferable container for whatever you build. Our how it works page walks through how that container gets created in practice.

How does a founder form the same kind of Delaware entity?

Pfizer's lawyers handle its filings; you do not have to. Forming a Delaware LLC follows a predictable path, and you can complete it from anywhere in the world without a US Social Security Number, visa, or address. The legal entity exists in about 48 hours after filing the Certificate of Formation; an EIN for your Delaware LLC follows, which takes 2 to 4 weeks for applicants without an SSN because the IRS processes those by fax or mail. After the EIN, a US business bank account is typically opened within 1 to 5 business days, though approval is always the bank's decision.

Our service is a flat $397, all-inclusive, with the Delaware state filing fee already included — there is no separate state charge to add on. From year two, a Delaware LLC owes a flat $300 franchise tax due June 1, with no annual report required for an LLC; miss the deadline and Delaware adds a $200 penalty plus 1.5% interest per month, which is why we track the date for you. The authorized-shares and assumed-par-value franchise-tax methods you may read about apply only to Delaware corporations, never to LLCs. For the full breakdown see our Delaware franchise tax and Delaware LLC cost pages.

If your business has non-US ownership, one federal filing matters most: a foreign-owned single-member Delaware LLC must file Form 5472 with a pro forma Form 1120 each year, due April 15 and extendable with Form 7004, with a $25,000 penalty under IRC 6038A for failing to file. We serve founders from 40+ countries and help you sequence formation, banking, Stripe, and US banking in the right order. Beneficial-ownership reporting under the Corporate Transparency Act has shifted: a March 2025 FinCEN interim final rule exempts US-formed domestic entities, leaving foreign reporting companies in scope, and the area is still evolving — confirm current status before relying on any summary. You will never build Pfizer, but you can start with the same Delaware foundation it is built on.

Many of these companies chose Delaware for the same reasons founders do today — the Court of Chancery, flexible LLC statutes, and strong privacy protections. Form your Delaware LLC for $397, all-inclusive, in 48 hours. Form your Delaware LLC → | Read the complete Delaware LLC guide →